Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals REGN.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 9 uncommon options trades for Regeneron Pharmaceuticals.

This isn't normal.

The overall sentiment of these big-money traders is split between 11% bullish and 88%, bearish.

Out of all of the special options we uncovered, 5 are puts, for a total amount of $307,767, and 4 are calls, for a total amount of $185,012.

Predicted Price Range

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $690.0 and $965.0 for Regeneron Pharmaceuticals, spanning the last three months.

Volume & Open Interest Trends

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's significant trades, within a strike price range of $690.0 to $965.0, over the past month.

Regeneron Pharmaceuticals 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Current Position of Regeneron Pharmaceuticals

• With a volume of 435,624, the price of REGN is down -0.03% at $958.71.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 48 days.

Professional Analyst Ratings for Regeneron Pharmaceuticals

A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1137.25.

• Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1184.
• An analyst from Morgan Stanley persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $1115.
• In a cautious move, an analyst from Bernstein downgraded its rating to Outperform, setting a price target of $1125.
• An analyst from Bernstein downgraded its action to Outperform with a price target of $1125.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.